Teladoc Health (TDOC) to Release Earnings on Wednesday

Teladoc Health (NYSE:TDOC) will likely be issuing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Teladoc Health to announce earnings of ($0.24) per share and revenue of $615.4460 million for the quarter. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The business had revenue of $613.85 million during the quarter, compared to the consensus estimate of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm’s revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.53) earnings per share. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Trading Down 0.5%

Shares of Teladoc Health stock opened at $8.72 on Monday. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.89. The company’s fifty day simple moving average is $8.05 and its 200-day simple moving average is $6.52. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -8.99 and a beta of 2.10. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Bank of America increased their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Citigroup boosted their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Finally, Canaccord Genuity Group increased their target price on shares of Teladoc Health from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.57.

Insider Transactions at Teladoc Health

In related news, insider Carlos Nueno sold 6,196 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the transaction, the insider directly owned 57,671 shares in the company, valued at approximately $440,029.73. This represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $145,977.16. Following the completion of the transaction, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 39,195 shares of company stock valued at $299,058. Company insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

A number of hedge funds and other institutional investors have recently made changes to their positions in TDOC. IFP Advisors Inc boosted its position in shares of Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares in the last quarter. Van ECK Associates Corp raised its position in Teladoc Health by 101.4% in the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after purchasing an additional 4,607 shares in the last quarter. Johnson Financial Group Inc. lifted its stake in Teladoc Health by 41,045.8% during the third quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock worth $76,000 after purchasing an additional 9,851 shares during the period. Finally, Envestnet Asset Management Inc. bought a new position in Teladoc Health during the second quarter worth about $89,000. 76.82% of the stock is owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.